Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs
LOS ANGELES, April 8, 2024 /PRNewswire/ — Solve M.E., the leading organization dedicated to advancing medical research and patient advocacy since 1987, is pleased to announce that Emily Taylor, Vice President of Advocacy and Engagement, has been appointed as President and CEO. Emily has been a
Two Barrels of Oil Per Day Is All Drillers Extract from Community Wells, Making Case For New Law For $10K Per Day Fine, says Consumer Watchdog
SACRAMENTO, Calif., April 8, 2024 /PRNewswire/ — Oil companies drilling for oil within a half mile of community residents produce a tiny trickle of oil—2.1 barrels of oil per day per well on average, according to new data from the FracTracker Alliance. Consumer Watchdog said the data makes
Milan Salone Del Mobile 2024: illycaffè to feature at the design industry’s most important international event
MILAN, April 8, 2024 /PRNewswire/ — illycaffè is getting ready for its star turn at the Milan Design Week. Those attending will find the global leader in high-quality sustainable coffee both at the Milan Furniture Fair and around the city at key events that celebrate the collision of beauty,
Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research
The caffeine powder market is anticipated to witness significant growth owing to growing popularity of sports and fitness activities worldwide. Athletes and fitness enthusiasts often use caffeine to improve endurance, reduce fatigue, and enhance exercise performance, contributing to the expansion o
femmes volcans forêts torrents – Nine women artists living in Québec featured at the MAC starting April 11
MONTRÉAL, April 8, 2024 /CNW/ – The Musée d’art contemporain de Montréal (MAC) is proud to unveil its latest exhibition, femmes volcans forêts torrents. Open to the public from April 11 to August 18, 2024, in the MAC’s temporary location at Place Ville Marie, this group exhibi
Shareholder Alert: Ademi LLP investigates whether Model N, Inc. has obtained a Fair Price in its transaction with Vista Equity Partners
MILWAUKEE, April 8, 2024 /PRNewswire/ — Ademi LLP is investigating Model N (NYSE: MODN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vista Equity Partners. Click here to learn how to join the https://www.ademilaw.com/case/model-n-inc or call Guri
47% of TAX FILERS DELAY FILING RETURNS
An independent national survey from TaxAct of over 1,100 tax filers revealed some would rather eat old sushi or clean the oven just to sidestep a little longer the unavoidable, dreaded duty that comes around this time of year. DALLAS, April 8, 2024 /PRNewswire/ — TaxAct® today released new
USPS Unveils Henry “Hank” Aaron Stamp On 50th Anniversary of Eclipsing Homerun Record
ATLANTA, April 8, 2024 /PRNewswire/ — The U.S. Postal Service today announced it will honor baseball legend Henry “Hank” Aaron with a commemorative Forever stamp. This stamp celebrates the life and career of Aaron (1934–2021), a giant both on and off the field, who rose from humb
SATLANTIS AND ENCINO ENVIRONMENTAL SERVICES ANNOUNCE ONE OF THE LARGEST COMMERCIAL CONTRACTS FOR SATELLITE-BASED METHANE DETECTION AND SUCCESSFUL LAUNCH OF SECOND METHANE SATELLITE
Encino acquires all data from orbits covering North America from SATLANTIS’ GEISAT to provide to North & South American clients in one of the largest commercial contracts for satellite-based methane emissions monitoring. SATLANTIS successfully launches HORACIO, its sixth successful mission
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1, which was well toleratedFollowing efforts to optimize allogeneic CAR-T therapy, Poseida is presenting a new data analysis u
